Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05929066 · ClinicalTrials.gov registry record · Phase 3
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight
A Phase 3 study of Obesity and Overweight, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 3
- Development phase
- 2,300
- Enrollment target
- 20
- Study locations
NCT05929066 is a Phase 3 study of Obesity and Overweight that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 2,300 participants, above the 817-participant average among 1,053 other Obesity trials with a reported enrollment target (182% higher). The trial reports 20 study locations across 10 states.
The verdict
NCT05929066, a Phase 3 study of Obesity and Overweight, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 2,300 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of retatrutide in participants who have obesity or overweight (J1I-MC-GZBJ master protocol) including subsets of participants who have knee osteoarthritis (OA) (J1I-MC-GOA1) or who have obstructive sleep apnea (OSA) (J1I-MC-GSA1). This study will last about 89 weeks and will include up to 24 visits. Addendum (2) is optional and available to approximately 500 participants to continue treatment with retatrutide for up to an additional 24 weeks.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Retatrutide
Study Locations (20)
Florida
- Teradan Clinical Trials, LLC - Brandon
- Suncoast Research Group - Miami
- New Horizon Research Center - Miami
- Clinical Neuroscience Solutions - Orlando
- Progressive Medical Research - Port Orange
California
- Neuro-Pain Medical Center - Fresno
- Valley Research - Fresno
- Artemis Institute for Clinical Research - San Diego
Arizona
- Central Phoenix Medical Clinic - Phoenix
- Arizona Research Center - Phoenix
Connecticut
- Yale University School of Medicine - New Haven
- Chase Medical Research, LLC - Waterbury
Georgia
- NeuroTrials Research Inc - Atlanta
- North Georgia Clinical Research - Woodstock
Illinois
- Northwestern University - Chicago
- Central Illinois Diabetes and Clinical Research a Division of Prairie Education and Research Cooperative - Springfield
Arkansas
- Medical Investigations - Little Rock
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,300 participants |
| Start Date | 2023-07-10 |
| Est. Completion | 2026-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05929066
The ClinicalTrials.gov registry entry for NCT05929066 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 2,300 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 817-participant average among 1,053 other Obesity trials with a reported enrollment target (182% higher). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05929066 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT05929066 about?
NCT05929066 is a clinical study titled "A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight". The purpose of this study is to evaluate the efficacy and safety of retatrutide in participants who have obesity or overweight (J1I-MC-GZBJ master protocol) including subsets of participants who have knee osteoarthritis (OA) (J1I-MC-GOA1) or who have obstructive sleep apnea (OSA) (J1I-MC-GSA1). This...
What is the current status of trial NCT05929066?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 2,300 participants. The study started on 2023-07-10. Estimated completion is 2026-05.
What conditions does trial NCT05929066 study?
This clinical trial studies the following conditions: Obesity, Overweight, Obstructive Sleep Apnea, Osteoarthritis, Knee.
What interventions are being tested in trial NCT05929066?
The interventions under investigation include: Placebo (DRUG), Retatrutide (DRUG).
Who is sponsoring clinical trial NCT05929066?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05929066 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
RECRUITING · Phase 3
-
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
RECRUITING · Phase 3
-
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.